Cirtec Medical ("Cirtec") is a leading global provider of outsourced medical device and components design, engineering and manufacturing, headquartered in Minnesota. Cirtec specialises in outsourced solutions for active implantable medical devices. Customers rely on Cirtec’s expertise to provide value-add solutions throughout the entire development cycle to help bring life-enhancing therapies to market.
The medical device outsourcing (MDO) market is expected to grow at a high single digit rate over the next five years and Cirtec is strategically indexed to the most innovative therapeutic end-markets that are growing at a rate beyond the broader MDO industry.
"We look forward to partnering with 3i. We feel that their approach, sector understanding and international reach makes them the right partner to support the next stage of our growth." Brian Highley, CEO, Cirtec
This transaction involved a recommendation of 3i Corporation, a US wholly owned subsidiary of 3i Group.
Havea Group is a leader in the Natural Consumer Healthcare industry in Europe. It manufactures, designs and distributes a wide range of products from functional and natural food supplements, to natural personal care products for babies and women through its world class plant in France. Havea is well positioned due to its multi-distribution channel strategy (pharma, mass market, D2C) and its 7 well-known strategic brands: Biolane, Vitavea, Nature Moi, Yves Ponroy, Aragan, Densmore and Dermovitamina. Havea has acquired 5 companies in the past 5 years to strengthen its presence in the pharmacy channel and internationally.
Since inception, Havea has grown at a double digit rate each year organically and is well positioned to benefit from the consolidation taking place in this highly fragmented market and will continue to expand its international footprint in Europe, Asia and the Americas.
"3i is a great partner for Havea; its values and approach fit really well with our entrepreneurial mindset. They relentlessly look for growth while keeping the right balance between operational performance improvement and the strengthening and digitalisation of our core processes. In 4 years with 3i, we have doubled the size of the Group and made 5 acquisitions, including my own company” Nicolas Brodetsky, CEO, Havea
This transaction involved a recommendation of 3i Investments plc, advised by 3i France.
Q Holding is a leading global manufacturer of highly-engineered, fully assembled medical devices and precision-molded elastomeric components used in a broad range of Life Sciences (medical and pharmaceutical) and Electrical Management (industrial, automotive and aerospace) applications. Headquartered in Ohio, it sells products in over 50 countries and has 13 manufacturing locations in North America, EMEA and Asia.
Q Holding has built a strong reputation as the supplier of choice to provide high-quality mission critical components for medical and harsh environment applications. It has developed longstanding relationships with a broad range of blue-chip customers who value Q’s ability to design and develop customized solutions and manufacture globally.
Regulatory information: This transaction involved a recommendation of 3i Corporation, a US wholly owned subsidiary of 3i Group.
3i has established a scaled, global, pure-play platform in the bioprocessing market by bringing together SaniSure, Cellon, TBL, and Silicone Altimex (together, “SaniSure”). SaniSure is a vertically-integrated player in the single-use bioprocessing technology (“SUT“) space capable of providing highly customised and innovative solutions to leading biopharma and biotech customers. The SUT bioprocessing market is anticipated to grow at 13-20%+ across its various subsegments over the coming years, as the industry transitions to more flexible, clean, and operating cost advantaged technology relative to traditional multi-use counterparts.
Recognising an attractive market opportunity characterised by high growth and a need for a leading independent platform of scale, 3i began a journey to create a single use bioprocessing platform in January 2020 with the carve-out of Silicone Altimex from 3i portfolio company, Q Holding, along with the acquisitions of founder-owned businesses TBL and Cellon.
Seven months later, in July 2020, the platform completed the transformative acquisition of founder-owned Sani-Tech West Inc. (Sani-Tech West and subsidiaries SaniSure® and SureTech), a leading US-based manufacturer, distributor and integrator of single-use bioprocessing systems and components. The acquisition significantly expanded the combined group’s global footprint and brought a complementary portfolio of innovative products and single-use solutions capabilities. The combined platform has robust manufacturing and cleanroom assembly operations in both North America and Europe, offering enhanced supply chain assurance to its customers with a global footprint and vertically integrated capabilities.
ten23 health was founded in 2021 and is a development, manufacturing and testing company for biotech start-ups and the established pharmaceutical industry.
Headquartered in Basel, Switzerland, ten23 health’s core service offering includes formulation development, drug product development and manufacturing, as well as testing services for sterile pharmaceutical products. These high-value services are critical to helping pharma and biotech customers turn a scientific concept and therapeutic modality into a viable sterile medicine that is optimised for manufacturability, patient access and ease of administration, and logistical favourability.
ten23 health embeds fairstainability in all its practices and decisions and puts the focus on people - customers, employees, patients - and the planet. The company aims for a net zero emissions target from inception, exhibiting its patient-centricity not only in the quality of service that it delivers, but also in its sustainability focus.
"3i’s demonstrated knowledge and deep understanding of the biotech landscape made them a clear partner in building ten23 health into a leader in the development, manufacturing and testing of injectable medicines.” Prof. Dr. Hanns-Christian Mahler, CEO ten23 health